Biocon Biologics Completes Global Biosimilars Integration Across 120 Countries Ahead of Schedule

19 Dec 2023 , 12:51 PM

Biocon Biologics completes the transition of its acquired biosimilars business in 120 countries, a year ahead of schedule. Over 10 emerging markets, Japan, Australia, and New Zealand transitioned in the final phase from the Viatris acquisition.

Biocon Biologics now has a robust commercial presence in 120 countries, including the United States, Canada, Europe, and key emerging markets: India, UAE, Saudi Arabia, Morocco, South Africa, Brazil, Malaysia, Thailand, and the Philippines.

Earlier transitions in 2023: Over 70 emerging markets integrated in July, North America business transitioned in September, and European business in November.

Shreehas Tambe, CEO and Managing Director of Biocon Biologics, expresses pride in successfully completing the integration across 120 countries, marking a significant milestone and the beginning of the company’s transformation into a fully-integrated global entity.

For feedback and suggestions, write to us at [e-mail]